Investigating Albumin Functionality in Hemodialysis Patients
Effects of Dialyzer Characteristics and Dialysis Mode on Functional Properties of Albumin in Patients With Chronic Hemodialysis Treatment
NA · Universität Duisburg-Essen · NCT06561191
This study is testing whether changing dialysis settings can improve the effectiveness of albumin in patients on hemodialysis and help them live healthier lives.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Universität Duisburg-Essen (other) |
| Locations | 1 site (Essen) |
| Trial ID | NCT06561191 on ClinicalTrials.gov |
What this trial studies
This study examines how different dialysis parameters, such as dialyzer properties and dialysis modes, affect the functional properties of albumin in patients undergoing hemodialysis. The goal is to determine if modifying these parameters can enhance treatment quality and reduce cardiovascular mortality associated with chronic kidney disease. By focusing on the relationship between albumin functionality and dialysis, the study aims to identify therapeutic strategies that could improve patient outcomes over the long term.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have been on a consistent hemodialysis regimen for at least three months.
Not a fit: Patients under 18 years old or those with acute or chronic liver disease, severe infections, or recent tumor diagnoses may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved hemodialysis treatments that enhance patient survival and reduce inflammation-related complications.
How similar studies have performed: Previous studies have indicated that optimizing dialysis parameters can positively impact patient outcomes, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years or older at least 3 month of hemodialysis treatment (3x/week) with constant dialysis treatment regimen Exclusion Criteria: * Age ≤ 18 years * Less than three months of regular (3x/week) hemodialysis treatments or less than 3 treatments/week * Acute or chronic liver disease (Child stage A or higher or fulfillment of the of the Kings College criteria) * Infusion of commercial human albumin (e.g. in the context of ascites drainage) in the last three months prior to study inclusion * Acute or severe chronic infections * Acute tumor disease
Where this trial is running
Essen
- University Hospital Essen — Essen, Germany (RECRUITING)
Study contacts
- Study coordinator: Kristina Boss, PD
- Email: kristina.boss@uk-essen.de
- Phone: 00492017231868
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Albumin, Dialysis, Redox State, Uremic, Toxemia